Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

INTRODUCTION: The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabberer, Maggie, Jones, C. Elaine, Kilbride, Sally, Halpin, David M. G., Lomas, David A., Pascoe, Steven, Singh, Dave, Wise, Robert A., Criner, Gerard J., Lange, Peter, Dransfield, Mark T., Han, MeiLan K., Martinez, Fernando J., Kaisermann, Morrys C., Lipson, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444357/
https://www.ncbi.nlm.nih.gov/pubmed/32647911
http://dx.doi.org/10.1007/s12325-020-01409-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444357/
https://www.ncbi.nlm.nih.gov/pubmed/32647911
http://dx.doi.org/10.1007/s12325-020-01409-8

Ejemplares similares